The prevalence of parvovirus B19 infection among pregnant women of Ardabil in 2013
-
Shahram Habibzadeh
,
Hadi Peeri Doghaheh
,
Jafar Mohammad Shahi
,
Elham Mobini
,
Samira Shahbazzadegan
Abstract
Background and Objectives: Trans-placental transmission of parvovirus B19 during pregnancy can causes adverse outcomes. Regarding its importance in prenatal care, we decided to study prevalence of parvovirus B19 infection among pregnant woman in Ardabil, Iran.
Materials and Methods: In a community based study with a cluster sampling, 350 pregnant women that attended in health care centers in Ardabil were selected. Serum samples were collected and Anti-B19 specific IgG was detected using commercial enzyme-linked immunosorbent assays (Euroimmune Elisa kit, Germany). Furthermore, a questionnaire filled for all participants during samples collection.
Results: 64.6% (226/350) of participants were Ardabil citizen and the rest were from rural area (124/350). Anti-B19-specific IgG antibody was detected in 69.1% of pregnant women (242/350). Participants' ages ranged from 15 to 34 years with average of 23 years. According to our study, seroprevalence of IgG antibodies had positive significant correlation with the participants' age (r=0.268) but there were no significant relations between B19 seropositivity and living area, family member, number of commensals, number of living children, and the amount of hemoglobin (p>0.05).
Conclusion: Approximately, one-third of the participants were at risk of primary B19 infection. Therefore, health education of pregnant women and screening of infected pregnant women is recommended to prevent fetal complications.
Peterlana D, Puccetti A, Corrocher R, Lunardi C. Se- rologic and molecular detection of human Parvovirus B19 infection. Clin Chim Acta 2006; 372: 14-23.
Brown KE (2012). Parvovirus infection. In: Harrison's principles of internal medicine. Eds, Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. McGraw-Hill, New York, pp 759-62.
Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262: 114-117.
Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997; 72: 1-10.
Mortimer PP, Luban NL, Kelleher JF, Cohen BJ. Trans- mission of serum parvovirus-like virus by clotting-fac- tor concentrates. Lancet 1983; 2: 482-4.
Noyola DE, Padilla-Ruiz ML, Obregón-Ramos MG, Zayas P, Pérez-Romano B. Parvovirus B19 infection in medical students during a hospital outbreak. J Med Microbiol 2004; 53: 141-146.
Feldman DM, Timms D, Borgida AF. Toxoplasmosis, parvovirus, and cytomegalovirus in pregnancy. Clin Lab Med 2010; 30: 709-720.
Crane J. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can 2002; 24: 727-43.
Woernle CH, Anderson LJ, Tattersall P, Davison JM.Human parvovirus B19 infection during pregnancy. J Infect Dis 1987; 156: 17-20.
Koch WC, Harger JH, Barnstein B, Adler SP. Serologic and virologic evidence for frequent intrauterine trans- mission of human parvovirus B19 with a primary ma- ternal infection during pregnancy. Pediatr Infect Dis J 1998; 17: 489-494.
Tolfvenstam T, Papadogiannakis N, Norbeck O, Peters- son K, Broliden K. Frequency of human parvovirus B19 infection in intrauterine fetal death. Lancet 2001;357: 1494-1497.
Erdman DD (1997). Human parvovirus B19: Labora- tory diagnosis. In: Monographs in Virology: Human Parvovirus B19, Eds, Anderson LJ, Young NS, Karger. Basel, pp. 93-104.
Giorgio E, De Oronzo MA, Iozza I, Di Natale A, Cianci S, Garofalo G, et al. Parvovirus B19 during pregnancy: a review. J Prenat Med 2010; 4: 63-66.
Rodis JF, Hovick TJ Jr, Quinn DL, Rosengren SS, Tat- tersall P. Human parvovirus infection in pregnancy. Obstet Gynecol 1988; 72: 733-738.
Valeur-Jensen AK, Pedersen CB, Westergaard T, Jen- sen IP, Lebech M, Andersen PK, et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA 1999;281: 1099-1105.
Jensen IP, Thorsen P, Jeune B, Moller BR, Vestergaard BF. An epidemic of parvovirus B19 in a population of 3,596 pregnant women: a study of sociodemographic and medical risk factors. BJOG 2000; 107: 637-643.
Ziyaeyan M, Rasouli M, Alborzi A. The seroprevalence of parvovirus B19 infection among to-be-married girls, pregnant women, and their neonates in Shiraz, Iran. Jpn J Infect Dis 2005; 58: 95-97.
Jensen IP, Schou O, Vestergaard BF. The 1994 human parvovirus B19 epidemic in Denmark: diagnostic and epidemiological experience. APMIS 1998; 106: 843-88.
Brown KE (2005). Parvovirus B19. In: Mandell, Doug- las, and Bennett's Principals and Practice of Infectious Diseases. Eds, Mandell GL, Bennett JE, Dolin R. Vol 2. 6th ed. Churchill Livingstone Elsevier. Philadelphia, PA, pp.1891-1902.
Isumi H, Nunoue T, Nishida A, Takashima S. Fetal brain infection with human parvovirus B19. Pediatr Neurol 1999; 21: 661-3.
James DK, Steer PJ, Weiner CP, Gonik B (2005). High Risk Pregnancy Manangement Option. In: Rubella, Measles, Mumps, Varicella and Parvovirus. Ed, Riley LE, 3rd ed. Sounders Philadelphia. pp 644-5.
Zajkowska A, Garkowski A, Czupryna P, Moniuszko A, Król ME, Szamatowicz J, Pancewicz S. Seropreva- lence of parvovirus B19 antibodies among young preg- nant women or planning pregnancy, tested for toxoplas- mosis. Przegl Epidemiol 2015; 69: 479-82, 597-600.
Sohrabi A, Samarbafzadeh AR, Makvandi M, Maraghi Sh, Razi T, Darban D. A seroepidemiological study of parvovirus B19, Toxoplasma Gondii and Chlamydia Tracomatis in pregnant woman referring to OBS & GYN ward of Ahwaz Imam Khomeini hospital, Iran. J Reprod Infertil 2007; 82: 171-175.
Emiasegen SE, Nimzing L, Adoga MP, Ohagenyi AY, Lekan R. Parvovirus B19 antibodies and correlates of infection in pregnant women attending an antenatal clinic in central Nigeria. Mem Inst Oswaldo Cruz 2011;106: 227-231.
Elnifro E, Nisha AK, Almabsoot M, Daeki A, Mujber N, Muscat J. Seroprevalence of parvovirus B19 among pregnant women in Tripoli, Libya. J Infect Dev Ctries 2009; 3: 218-20.
Khameneh ZR, Hanifian H, Barzegari R, Sepehrvand N. Human parvovirus B19 in Iranian pregnant women: a serologic survey. Indian J Pathol Microbiol 2014; 57: 442-444.
Abiodun I, Opaleye OO, Ojurongbe O, Fagbami AH.Seroprevalence of parvovirus B19 IgG and IgM anti- bodies among pregnant women in Oyo State, Nigeria. J Infect Dev Ctries 2013; 7: 946-950.
Cohen B. Parvovirus B19: an expanding spectrum of disease. BMJ 1995; 311: 1549-52.
Shahraki S, Moradi A, Ebrahimi Tabas A, Sanei Mogha- dam E. B19 parvovirus in 15-45 year-old women in Sar- avan in 2001. J Zanjan Univ Med Sci 2003; 11: 37- 40.
| Files | ||
| Issue | Vol 8 No 3 (2016) | |
| Section | Articles | |
| Keywords | ||
| Seropositive Infection Parvovirus B19 Pregnant women | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
